Cargando…

ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion

Chromosomal translocation t(8;21)(q22;q22) which leads to the generation of oncogenic RUNX1-RUNX1T1 (AML1-ETO) fusion is observed in approximately 10% of acute myelogenous leukemia (AML). To identify somatic mutations that co-operate with t(8;21)-driven leukemia, we performed whole and targeted exom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madan, Vikas, Han, Lin, Hattori, Norimichi, Teoh, Weoi Woon, Mayakonda, Anand, Sun, Qiao-Yang, Ding, Ling-Wen, Nordin, Hazimah Binte Mohd, Lim, Su Lin, Shyamsunder, Pavithra, Dakle, Pushkar, Sundaresan, Janani, Doan, Ngan B., Sanada, Masashi, Sato-Otsubo, Aiko, Meggendorfer, Manja, Yang, Henry, Said, Jonathan W., Ogawa, Seishi, Haferlach, Torsten, Liang, Der-Cherng, Shih, Lee-Yung, Nakamaki, Tsuyoshi, Wang, Q. Tian, Koeffler, H. Phillip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269306/ https://www.ncbi.nlm.nih.gov/pubmed/30093396 http://dx.doi.org/10.3324/haematol.2018.189928

Ejemplares similares

Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in mice
por: Han, Lin, et al.
Publicado: (2019)

Dissecting the role of SWI/SNF component ARID1B in steady-state hematopoiesis
por: Madan, Vikas, et al.
Publicado: (2023)

CARD10, a CEBPE target involved in granulocytic differentiation
por: Shyamsunder, Pavithra, et al.
Publicado: (2018)

ZRSR1 co-operates with ZRSR2 in regulating splicing of U12-type introns in murine hematopoietic cells
por: Madan, Vikas, et al.
Publicado: (2021)

THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors
por: Shyamsunder, Pavithra, et al.
Publicado: (2022)

Identification of somatic alterations in lipoma using whole exome sequencing
por: Kanojia, Deepika, et al.
Publicado: (2019)

Role of ASXL1 mutation in impaired hematopoiesis and cellular senescence
por: Uni, Masahiro, et al.
Publicado: (2018)

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations
por: Lim, Su Lin, et al.
Publicado: (2019)

Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome
por: Madan, Vikas, et al.
Publicado: (2015)

Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation
por: Nagase, Reina, et al.
Publicado: (2018)

Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
por: Meggendorfer, Manja, et al.
Publicado: (2017)

Experimental ASXL1 ‐Mediated Clonal Hematopoiesis Promotes Inflammation and Accelerates Heart Failure
por: Min, Kyung‐Duk, et al.
Publicado: (2022)

Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia
por: Baer, Constance, et al.
Publicado: (2021)

ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis
por: Li, Zhaomin, et al.
Publicado: (2017)

Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
por: Hattori, Norimichi, et al.
Publicado: (2019)

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations
por: Höllein, Alexander, et al.
Publicado: (2019)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia
por: Walter, Wencke, et al.
Publicado: (2021)

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

S161: UBA1 NON-M41 VARIANTS ARE MORE AGGRESSIVE THAN UBA1 M41 VARIANTS IN THEIR HEMATOLOGICAL MANIFESTATIONS.
por: Sakuma, Maki, et al.
Publicado: (2023)

P690: IDENTIFICATION OF CLINICALLY RELEVANT VARIANT-LEVEL SEX-BIAS IN SF3B1 K700/K666 AND IDH2 R140/R172
por: Sakuma, Maki, et al.
Publicado: (2023)

“Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing?
por: Baer, Constance, et al.
Publicado: (2019)

Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis
por: Müller, Heiko, et al.
Publicado: (2022)

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis
por: Huber, Sandra, et al.
Publicado: (2022)

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase
por: Huber, Sandra, et al.
Publicado: (2022)

P689: CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?
por: Haferlach, Claudia, et al.
Publicado: (2023)

Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR
por: Mas-Peiro, Silvia, et al.
Publicado: (2023)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

MDS subclassification—do we still have to count blasts?
por: Huber, Sandra, et al.
Publicado: (2023)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Increased prevalence of clonal hematopoiesis of indeterminate potential in hospitalized patients with COVID-19
por: Schenz, Judith, et al.
Publicado: (2022)

Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
por: Lim, Su-Lin, et al.
Publicado: (2020)

Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies
por: Sakuma, Maki, et al.
Publicado: (2023)

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts
por: Huber, Sandra, et al.
Publicado: (2022)

AML classification in the year 2023: How to avoid a Babylonian confusion of languages
por: Huber, Sandra, et al.
Publicado: (2023)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

P1213: ARTIFICIAL INTELLIGENCE TO PREDICT MEDICAL DIAGNOSIS FROM FLOW CYTOMETRIC RAW DATA IN MATURE B-CELL AND T-CELL NEOPLASMS, AML, ALL, MDS AND MULTIPLE MYELOMA
por: Müller, Martha-Lena, et al.
Publicado: (2023)

Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3)
por: Ayoub, Maya C., et al.
Publicado: (2023)

A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation
por: Imataki, Osamu, et al.
Publicado: (2020)

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
por: Huber, Sandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7cbtggcbhm3ev32puvdqqs2sak